Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Want to cut your energy bills? Here’s how five experts are doing it 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
NEW YORK, March 15, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Rockwell Medical, Inc. (“Rockwell” or the “Company”) (Nasdaq:RMTI) between September 9, 2015 and February 29, 2016.
You are hereby notified that a securities class action has been commenced in the USDC for the Southern District of New York. If you purchased or otherwise acquired Rockwell securities between September 9, 2015 and February 29, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/rockwell-medical.
The complaint alleges that the Company failed to disclose that: (1) Rockwell’s main product offering for Triferic has not yet been approved by the FDA; and (2) Rockwell is seeking to obtain transitional add-on payment reimbursement for Triferic with the Centers for Medicare & Medicaid Services instead of bundled reimbursement.
If you suffered a loss in Rockwell you have until May 3, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/rockwell-medical.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
